Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities
Net loss	$ (4,324,106)	$ (2,096,951)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	610	608
Research and development-acquired license, expensed	362,500	20,000
Warrants issue for acquired license	32,015
Stock-based compensation	7,762	290,075
Realized gain on marketable securities	(4,892)
Unrealized loss on marketable securities	(2,973)
Changes in assets and liabilities:
Prepaid expenses	53,335	(88,964)
Accounts payable	(104,544)	64,986
Net cash used in operating activities	(3,980,293)	(1,810,246)
Cash flows from investing activities
Purchase of investments in joint venture	(410,000)
Purchase of research and development licenses	(77,500)	(20,000)
Purchase of marketable securities	(1,500,000)
Sale of marketable securities	300,000
Net cash used in investing activities	(1,687,500)	(20,000)
Cash flows from financing activities
Proceeds from issuance of common stock in the IPO, net of offering cost		5,840,168
Proceeds from issuance common stock and warrants, net of offering cost	4,193,756
Proceeds from issuance common stock, net of offering cost	4,475,000
Proceeds from exercise of warrants	56,250	163
Net cash provided by financing activities	8,725,006	5,840,331
Effect of exchange rate changes on cash and cash equivalents	(662)
Net increase in cash	3,056,551	4,010,085
Cash and restricted cash, beginning of period	1,890,866	282,621
Cash and restricted cash, end of period	4,947,417	4,292,706
Non-cash investing and financing activities
Conversion of preferred stock to common stock upon completion of the IPO		310
Unpaid offering cost included in accrued expenses		27,127
Cancellation and retirement of common stock	2
Cashless warrant exercise		$ 22